Terumo Corporation · TSE:4543

Terumo — Investor Presentation (July 2011)

5 slides from Terumo's investor presentation, Jul 28, 2011

  1. Slide 1: Growth Strategy Gains Momentum

    Growth Strategy Gains Momentum Terumo Corporation President & Representative Director Yutaro Shintaku July 28, 2011

  2. Slide 2: Hands-on Approach for Unifying CaridianBCT

    Hands-on Approach for Unifying CaridianBCT 2011/7/28 Terumo Corporation 2/5

  3. Slide 3: New Opportunities with BCT Technologies

    New Opportunities with BCT Technologies The first autologous cellular immunotherapy (Cancer vaccine) in business <Example: Prostate cancer> U.S. cancer vaccine company FDA approval in Apr, 2010 CaridianBCT Spectra® Collect blood containing Derive dendritic Introduce antigen onto Administer to lots o

  4. Slide 4: Further Potential

    Further Potential Ce ll ular Imm un othe ra p y Cell Therapeutic Expansion Aphaeresis Utilizing cells and growth factors, Myocardial Regeneration into Regenerative Medicine Myocardial patch mi a he r y isc a o r ona chemi t o f c m b is t m en nic li a Tre & Chro Cell deriving 2011/7/28 Terumo Corpo

  5. Slide 5: IR Contact

    IR Contact TERUMO Corporation Corporate Communication (IR) Dept. E-mail: [email protected] Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo

Terumo — Investor Presentation (July 2011) on 6ix